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Communication about prescription drugs ought to be a paragon of
public science communication. Unfortunately, it is not. Consumers
see $4 billion of direct-to-consumer advertising annually, which
typically fails to present data about how well drugs work. The
professional label—the Food and Drug Administration’s (FDA)
mechanism to get physicians information needed for appropriate
prescribing—may also fail to present benefit data. FDA labeling
guidance, in fact, suggests that industry omit benefit data for new
drugs in an existing class and for drugs approved on the basis of
unfamiliar outcomes (such as depression rating scales). The medical
literature is also problematic: there is selective reporting of favor-
able trials, favorable outcomes within trials, and “spinning” unfa-
vorable results to maximize benefit and minimize harm. In contrast,
publicly available FDA reviews always include the phase 3 trial data
on benefit and harm, which are the basis of drug approval. How-
ever, these reviews are practically inaccessible: lengthy, poorly
organized, and weakly summarized. To improve accessibility, we
developed the Drug Facts Box: a one-page summary of benefit and
harm data for each indication of a drug. A series of studies—including
national randomized trials—demonstrates that most consumers un-
derstand the Drug Facts Box and that it improves decision-making.
Despite calls from their own Risk Communication Advisory Commit-
tee and Congress (in the Affordable Care Act) to consider implement-
ing boxes, the FDA announced it needs at least 3–5 y more to make
a decision. Given its potential public health impact, physicians and the
public should not have to wait that long for better drug information.
physician–patient communication | evidence summaries | data presentation
Communication about prescription drugs ought to be a para-gon of public science communication. Prescription drugs
are important: they can literally be a matter of life and death.
Americans take a lot of them: nearly half of the US population
takes at least one prescription drug every day; two-thirds of those
over age 65 y take at least three (1). Poor communication can
have serious consequences: people may forgo drugs that can help
or take drugs with no benefit or that even cause harm.
In the past, the public was not the intended audience for pre-
scription drug information. According to the 1938 regulations
establishing the modern US Food and Drug Adminstration (FDA),
for example, it was expected that information in drug labels would
“appear only in such medical terms as are not likely to be un-
derstood by the ordinary individual.” (2) However, much has
changed since 1938. With the rise of the consumer movement in
society, the shift in medicine from paternalism to respect for pa-
tient autonomy, and the expansion of the medical–industrial com-
plex, the public is now the audience for a vast amount of drug
information—most obviously in the form of direct-to-consumer
(DTC) drug advertising.
Although DTC advertising in the United States began in earnest
in the mid-1990s, it remains controversial (in fact, New Zealand
is the only other country permitting such advertisements) (3–
8). Proponents argue that the advertisements have an educa-
tional function, raising consumer awareness about a variety of
medical conditions and educating them about treatment options.
Opponents, however, worry that the advertisements mostly in-
crease inappropriate demand for marginally effective drugs.
Current investment in DTC advertising is substantial. Pharma-
ceutical companies spent more than $4 billion in 2011 on DTC
advertisements (9), about 10 times FDA’s total budget for the
evaluation of new drugs (10). In the United States, DTC adver-
tisements are ubiquitous. The average American television watcher
views about 15 h of them per year (11). DTC print advertisements
appear in nearly every major US newspaper and magazine.
DTC advertising also influences physicians—as do other market-
ing efforts such as advertisements in medical journals and detailing
visits from pharmaceutical representatives. However, physicians
mostly learn about prescription drugs from medical journal articles
and other professional sources. None is more important than the
FDA-approved drug label. Whether they realize or not, physicians
get information from the label all of the time. The Physicians Desk
Reference is a compendium of labels, and popular electronic
medical sources such as UpToDate reprint excerpts of the label.
In this paper, we will look at problems with how prescription
drug information is presented to consumers and doctors. To illus-
trate these problems, we use the example of Abilify (aripiprazole),
an antipsychotic drug most recently approved for the treatment
of depression that is only partially responsive to another anti-
depressant (the drug is also approved for a variety of other dis-
orders). Abilify—the fourth most heavily advertised drug in the
United States (9)—had sales of more than $5 billion last year
(12). The problems we describe below in advertisements, labels, and
journal articles are general: they are neither unusual nor unique to
Abilify. Moreover, all are “legal”—none violate federal regulations.
We end by describing the Drug Facts Box: a standardized one-page
summary designed to improve communication of key information
about benefits and harms of prescription drugs.
Problems with Drug Information for Consumers
DTC Advertising. The multimedia “Me and my depression” Abilify
advertising campaign exemplifies how the drug is being intensely
promoted to consumers. One ad features a cartoon image of
a woman being dragged down by a ball and chain who says “After
6 weeks on an antidepressant, I was still struggling with my de-
pression”; the ad then suggests that people ask their doctor about
adding Abilify to their drug regimen. However, the ad never says
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how well the drug works. That information is not available on ei-
ther the front page (glossy visual page) or on the required second
text page called the “brief summary” (Table 1).
Unfortunately, this is the rule rather than the exception; few
print DTC advertisements provide data on drug benefit (4, 13).
In a content analysis of DTC advertisements in popular magazines,
we found that only 13% of advertisements provided any data on
drug benefit (13). Instead, advertisements typically asserted drug
benefits with vague qualitative statements (e.g., a celebrity saying
“It works for me”). This situation may seem surprising given
the FDA regulation that states that “all advertisements for any
prescription drug shall present a true statement of information
in brief summary relating to side effects, contraindications, and
effectiveness.” Although in ordinary use the word “effectiveness”
means how well a drug works, FDA interprets the word to mean
indication—what the drug is used for. Under this interpretation,
advertisements without benefit data satisfy the regulation as long
as they include the drug’s indication.
The minority of advertisements that do present data typically use
formats that tend to exaggerate the magnitude of the benefit (13).
For example, a recent Lipitor advertisement claimed “Lipitor cuts
the risk of stroke by nearly half” but never says half of what (the
chance of stroke without Lipitor). The “nearly half” statistic (the
relative risk reduction) reported in the ad corresponds to a change in
the risk of stroke over 4 y from 2.8% with Lipitor to 1.5% without
Lipitor—an absolute difference of 1.3 percentage points. Numerous
studies have demonstrated that relative risk reductions without the
“of what” lead patients and physicians to overestimate a drug’s
benefit (14–16).
In contrast to how they treat benefits, DTC advertisements
always include information about side effects. In fact, side effect
information is often overwhelming: some present laundry lists
on the front page of the ad (occasionally quantified) and some
in tables (often quantified) in the brief summary. In the Abilify
“Me and My depression” print ad, the side effects are neither
organized into any hierarchy of importance, nor are they
quantified. As a result, it is hard for readers to know which side
effects matter or how often they occur. For example, a poten-
tially serious side effect called akathisia (a severe inability to
keep still) is downplayed by its inclusion in a list that surrounds
Fig. 1. Drug Facts Box for Abilify for adults with major depression that persists on antidepressants.
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it with mild symptom side effects such as headache, dizziness,
and nausea.
Medication Guides. Medication guides are informational sheets re-
quired fordrugs that theFDAdeems tohave serious sideeffects (17).
The guides are given to patients at the pharmacy when prescriptions
are filled in an effort to promote the safe use of drugs. Like all
medication guides, the Abilify Guide does not discuss the drug’s
benefit (18). It onlymentions the drug’s indication, and like theDTC
ad, the medication guide fails to prioritize or quantify side effects.
Problems with Drug Information for Physicians
FDA-Approved Drug Label. The prescription drug label (also known
as the package insert) summarizes the safe and effective use of
the drug. The primary purpose of the label “is to give healthcare
professionals the information they need to prescribe drugs ap-
propriately” (19). Although many doctors and patients assume
that the FDA writes drug labels, they are actually written by the
pharmaceutical companies who produce the drugs. The FDA’s
role is reviewing and approving the labels (FDA approval must be
obtained before a drug can be marketed). Unfortunately, despite
FDA approval, important information about how well drugs
work may be missing from the label (20, 21). For example, a
4-mg dose of Zometa (zoledronic acid) was approved for treating
hypercalcemia of malignancy. The FDA label warns that the
unapproved 8-mg dose causes renal toxicity—but does not mention
the doubling of mortality observed with this dose in the phase III
trials from 19% to 33% (20). The label for Rozerem (ramelteon),
a “sleeping pill” approved to reduce time to fall asleep, fails to
acknowledge important uncertainties about the drug’s benefit.
The FDA review team leader (22) was concerned that
“The applicant has conducted a significant number of studies in the
course of the development of ramelteon.... However, after approxi-
mately 3,500 patients being exposed to ramelteon in various studies,
the final assessment is that ramelteon has a statistically significant
treatment effect that is of marginal clinical significance. . . .. . .patients
who are currently being targeted by the proposed indication do not
seem to recognize any benefit from treatment with ramelteon.”
Nor did the label for the recently approved 23-mg dose of
Aricept (donepezil) to treat dementia alert physicians that the
FDA’s medical and its statistical reviewers recommended against
approval because the drug did not meet prespecified criteria de-
fining a clinically meaningful benefit (21).
The Abilify label typifies another problem: it presents no benefit
data at all (23). Instead, it merely states that the drug “was su-
perior to placebo in reducing mean MADRS total scores” (Table
2). We documented a similar absence of benefit data in the
FDA-approved labels for Lunesta (esziclopine) and Rozerem
(20). This problem is not surprising because the FDA’s own
Guidance for Industry recommends omitting benefit data from
the label under certain circumstances (24). Specifically, the FDA
guidance recommends “less detail” when
“The new drug appears to have effects that are typical of its class”;
or when “the magnitude of the effect on clinical endpoints measured
in the study is not readily translatable into effects in clinical practice.
Table 1. Prescription drug information for consumers
Statements Problem
Direct to consumer ad
Benefit (complete text)
“After 6 weeks on an antidepressant, I was still struggling with my depression.” Neither the ad nor brief summary provide
any data on benefitIf you have been on an antidepressant for at least 6 wk and are still struggling
with depression, having ABILIFY added to your antidepressant may help with
unresolved symptoms in as early as 1–2 wk.
ABILIFY is a prescription drug used to treat depression in adults as add-on
treatment to an antidepressant when an antidepressant alone is not enough.
Side effects (excerpt)
Antidepressant symptoms can increase suicidal thoughts and behavior in children,
teens, and young adults. ...high fever, rigid muscles, shaking, confusing,
sweating or increased heart rate and blood pressure, these may be signs of
a rare by potentially fatal condition, called neuroleptic malignant syndrome.
No explicit organization of side effects and no data
on frequency due to the drug.
Commons side effects in adults in clinical trials (>10%) include nausea,
vomiting, constipation, headache, dizziness, an inner sense of restlessness
or need to move (akathisia), anxiety and insomnia).
Akathisia—a severe restlessness that makes it hard to
keep still—is downplayed by inclusion in a list with
common symptom side effects like headache.
Medication guide
Benefit (complete text)
None (other than mention of indication) No discussion of benefit
Side effects (excerpt)










No explicit organization of side effects and no data
on frequency due to the drug.
Akathisia is downplayed by inclusion in a list with
common symptom side effects like headache.
Quoted text is shown in bold.
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For example, exercise testing in a study of heart failure can demon-
strate effectiveness, but does not translate into a quantifiable clinical
outcome. Similarly, changes in HAM-D [Hamilton depression rating
scale] scores can be used to demonstrate effectiveness of an antide-
pressant, but the results for a given study are population- and probably
site-specific, and thus, do not necessarily translate to a numerically
similar outcome in clinical practice. In these cases, it could be useful
to describe the study in general terms (e.g. population, duration,
endpoints measured and qualitative outcome) without providing
detailed results.”
Without benefit data, doctors cannot possibly judge how well
a drug works. Not reporting benefit data for new drugs in an
established class or drugs approved based on outcomes with
uncertain clinical meaning or using unfamiliar scales does not
solve the problem but makes it worse. Instead, the FDA should be
clear about the magnitude (and meaning) of the effect that
merited approval, to whom it applies, and translate the benefit into
clinically meaningful terms or explicitly acknowledge that the drug
may not have a clinically important effect.
Medical Journal Article. Published reports of clinical trials in med-
ical journals are another important source of drug information for
physicians. Unfortunately, a growing body of literature has docu-
mented disturbing problems with the quality of published research
reports, particularly when they are industry sponsored, including
selective publication of trials with favorable results (25–29),
Table 2. Prescription drug information for physicians
Quoted text is shown in bold.
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selective reporting of favorable outcomes (26, 30, 31), and
“spinning” results and conclusions to overstate the benefit of an
intervention (32–34) or to minimize the side effects (35).
There is evidence of “spin” in the journal articles (Table 2)
reporting on the two Abilify studies that were the basis of its
approval by the FDA for depression that persists despite an an-
tidepressant (36, 37). In both articles (36, 37), the benefit of the
drug was magnified visually by presenting graphs with extremely
truncated axes (e.g., only 10 points of a 60-point scale, only 1.4
points of a 10-point scale). Side effectswere alsodownplayed in both
articles: the conclusions of each abstract referred to the drug as being
“well tolerated,”despite a sixfold increase in akathisia amongpatients
randomized to the drug compared with placebo: 25% vs. 4%.
Medical journals have a responsibility to avoid publishing bi-
ased trials or allowing misleading reports of trial results. Ongoing
efforts initiated by medical journal editors are mitigating these
problems to some extent. For example, clinical trial registration in
a public registry (such as clinicaltrials.gov) before patient enroll-
ment is now a condition for publication (38); journals are encour-
aged to review the trial protocol along with the manuscript (39),
and journals are trying to implement reporting guidelines such as
CONSORT (Consolidated Standards of Reporting Trials) (40).
Unfortunately, even these efforts may not be sufficient to control
spin, which will require substantial ongoing editorial attention.
How to Do Better
To make informed decisions, doctors and consumers need to
weigh drug benefits and side effects. Unfortunately, consumers
and even physicians may have difficulty finding the relevant in-
formation. In contrast to DTC advertisements, medical guides,
FDA labels, and medical journal articles, benefit and side effect
data are always available in FDA review documents. FDA re-
viewers with clinical, statistical, chemical, pharmacologic, and
epidemiologic expertise write these documents after spending
up to 1 y reviewing the evidence submitted in the pharmaceutical
company’s drug approval application. Usually this evidence con-
sists of at least two phase 3 randomized clinical trials in patients
with a specific condition (the indication sought for approval). The
FDA review documents (publicly available at www.accessdata.fda.
gov/scripts/cder/drugsatfda/) provide a detailed description of all
of the phase 3 clinical trial data considered. They also provide
important insight into how reviewers decided whether the drug
offered a meaningful benefit and whether the benefit exceeded
harms. Unfortunately, the review documents are practically in-
accessible: they are lengthy (typically hundreds of pages long),
poorly organized, and weakly summarized.
To make such information accessible, we developed the Drug
Facts Box: a simple one-page summary of drug benefit and side
effect data for a given indication of a drug. The central feature of
the box is a data table with the absolute risks of various outcomes
with and without the drug. The data are from the FDA review
documents, supplemented by high quality systematic reviews.
Creating boxes requires many decisions, including which data
to present (which trials, which outcomes) and how to present it
(means or percentages, how to communicate statistical significance,
etc.). To make these decisions transparent and reproducible, we
developed a handbook with both general principles and specific
guidance on drafting boxes. We pilot tested the handbook in
October 2007 with seven FDA medical reviewers who drafted
boxes (in the hope that, in the future, FDA reviewers would
routinely write boxes for all newly approved drugs). We revised the
handbook based on feedback from the FDA reviewers and from
independent drug experts outside the FDA.
A Drug Facts Box for Abilify for major depression that persists
on antidepressants (Fig. 1) summarizes the combined data from
the two identical 6-wk randomized trials that were the basis for
FDA drug approval for this indication (41). The box shows that
Abilify has only a modest benefit: on average, patients on Abilify
improved by 3 points more (on a scale of 60) than patients on
placebo, and only an additional 11% of patients had a clinically
important response as defined in the trial: a 50% or greater
reduction in their depression score and no longer meeting the
criterion for major depression [i.e., a 6-wk follow-up depression
score less than 10 on the Montgomery–Åsberg depression rating
scale (MADRS)]. The box also highlights Abilify’s most important
side effects: an additional 21% of patients experienced akathisia
(severe restlessness), and an additional 4% gained a substantial
amount of weight. The box alerts readers to the fact that Abilify—
like all antidepressants—can cause a small increase in suicidal
thoughts and behavior among young adults, and that Abilify, like
all antipsychotics, can also cause a variety of uncommon but life-
threatening side effects.
We envision two versions of boxes: one for consumers and
another for physicians. The consumer version (such as the Abilify
Box; Fig. 1) would be based on the longest, largest phase 3 trial
measuring patient as opposed to surrogate outcomes (data from
identical replication trials would be combined if the results
were similar). The physician version would present more details,
for example, specific outcome scales used (e.g., “depression score
was measured with MADRS”) and the cutoffs selected for di-
agnostic thresholds. The physician version would also include data
tables for all phase 3 trials submitted to the FDA.
The Drug Facts Box can improve prescription drug communi-
cation in multiple ways. It can educate physicians and provide
them with an unbiased summary of drug benefit and side effects
using the same data the FDA used in the drug approval process. It
can educate consumers by filling in important gaps that exist in
current informational sources such as drug advertisements and
medication guides. Also, it can foster better physician–patient com-
munication by facilitating evidence-based discussions about drugs.
When we first proposed the Drug Facts Box, the FDA expressed
concern about whether consumers could understand the data.
Based on a series of studies, we are confident that most can (42–
46). The first study (n = 203) tested consumer comprehension of
the benefit portion of the box: for example, 97% were able to
correctly read percentages from the data table (45). The second
study (n = 274) tested a full box for the drug Tamoxifen for
preventing first breast cancers (42). This more complex table
included nine rows and two columns of data. On average, par-
ticipants correctly answered four out of five data comprehension
questions. In a nationally representative randomized trial (n = 231),
68% of people randomized to see DTC advertisements with drug
boxes chose the objectively better of two heartburn drugs com-
pared with 31% of people seeing standard advertisements (44).
Most recently, we conducted two national randomized trials
(both n = 2,944) to test features of the box. One trial tested
simplified numeric formats: percentages alone were as good and
sometimes better than the original combination format of per-
centages plus frequencies (46). Based on this finding, we now use
percentages alone. The other trial found that brief explanations
about surrogate outcomes and the safety of new prescription
drugs improved drug choices: 71% (explanation group) vs. 59%
(control) chose the cholesterol drug that reduced heart attacks
over the one that only reduced cholesterol levels; 53% (expla-
nation group) vs. 34% (control) chose the equally effective older
drug over a newly approved drug (43).
Based in part on the foregoing studies, the FDA’s Risk Com-
munication Advisory Committee (47) and Congress (48) called
on the FDA to consider implementing Drug Facts Boxes. Un-
fortunately, the FDA has said it needs an additional 3–5 y to
study the evidence. Given its potential public health impact,
physicians and the public should not have to wait that long for
better drug information. They should have access now. In fact,
the FDA’s own evidence-based user’s communication guide says,
“It is imperative to provide patients with numerical estimates of
the risks and benefits associated with treatment options.” (49) If
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the FDA is unable to clearly and succinctly communicate what
it knows—and does not know—about the drugs it approves, then
it is time for another independent entity to do it for them.
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